BryoLogyx is developing a new class of drugs to enhance the response rates and
treatment durability of cancer immunotherapies and anti-HIV agents. The company’s initial focus
is on cancer, where it is capitalizing on two recent scientific advances: the discovery
that a complex natural product, bryostatin, stimulates tumor antigen production to amplify
the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic
production method for bryostatin and analogs, enabling their availability for commercial development.
BryoLogyx has exclusive rights from Stanford University to the method’s use in the areas of cancer and HIV.
Bryostatin, currently in development for use with immuno-oncology agents,
has an established safety profile based on clinical studies involving more than 1100 patients.